Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Korell, Felix [VerfasserIn]   i
 Schubert, Maria-Luisa [VerfasserIn]   i
 Sauer, Tim [VerfasserIn]   i
 Schmitt, Anita [VerfasserIn]   i
 Derigs, Patrick [VerfasserIn]   i
 Weber, Tim [VerfasserIn]   i
 Schnitzler, Paul [VerfasserIn]   i
 Müller-Tidow, Carsten [VerfasserIn]   i
 Dreger, Peter [VerfasserIn]   i
 Schmitt, Michael [VerfasserIn]   i
Titel:Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma
Verf.angabe:Felix Korell, Maria-Luisa Schubert, Tim Sauer, Anita Schmitt, Patrick Derigs, Tim Frederik Weber, Paul Schnitzler, Carsten Müller-Tidow, Peter Dreger and Michael Schmitt
E-Jahr:2021
Jahr:2 April 2021
Umfang:12 S.
Fussnoten:Gesehen am 18.02.2022
Titel Quelle:Enthalten in: Cancers
Ort Quelle:Basel : MDPI, 2009
Jahr Quelle:2021
Band/Heft Quelle:13(2021), 7, Artikel-ID 1684, Seite 1-12
ISSN Quelle:2072-6694
Abstract:Chimeric antigen receptor T (CAR-T) cell therapy has proven to be very effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). However, infections—related either due to lymphodepletion or the CAR-T cell therapy itself—can result in severe and potentially life-threatening complications, while side effects such as cytokine release syndrome (CRS) might complicate differential diagnosis. Sixty-seven dosings of CAR-T cells in sixty adult patients with NHL (85%) and ALL (15%) receiving CAR-T cell therapy were assessed for infectious complications. Almost two-thirds of patients (61%) developed fever following lymphodepletion and CAR-T cell dosing. Microbiological or radiological findings were observed in 25% of all cases (bacterial 12%, viral 5%, fungal 8%). Inpatient infections were associated with more lines of therapy and more severe CRS. However, overall serious complications were rare after CAR-T therapy, with one patient dying of infection. Pathogen detection after inpatient stay was infrequent and mostly occurred in the first 90 days after dosing. Infections in CAR-T cell treated patents are common. Fast and suitable identification and treatment are crucial in these heavily pretreated and immunocompromised patients. In most cases infectious complications are manageable. Nonetheless, standardized anti-infective prophylaxis and supportive therapy are mandatory to reduce morbidity and mortality in CAR-T cell therapy.
DOI:doi:10.3390/cancers13071684
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: https://doi.org/10.3390/cancers13071684
 Volltext: https://www.mdpi.com/2072-6694/13/7/1684
 DOI: https://doi.org/10.3390/cancers13071684
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:CAR-T cell
 cytokine release syndrome
 infection
 lymphodepletion
K10plus-PPN:1790093759
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68880467   QR-Code
zum Seitenanfang